Idiopathic Inflammatory Myopathies Clinical Trials

17 recruiting

Idiopathic Inflammatory Myopathies Trials at a Glance

24 actively recruiting trials for idiopathic inflammatory myopathies are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Iowa City, Toulouse, and Brest. Lead sponsors running idiopathic inflammatory myopathies studies include AstraZeneca, Tongji Hospital, and University Hospital, Brest.

Browse idiopathic inflammatory myopathies trials by phase

Treatments under study

About Idiopathic Inflammatory Myopathies Clinical Trials

Looking for clinical trials for Idiopathic Inflammatory Myopathies? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Idiopathic Inflammatory Myopathies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Idiopathic Inflammatory Myopathies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled35 locationsNCT06916806
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Early Phase 1

MTS109 in Patients With Refractory Autoimmune Diseases

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Early Phase 1

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

SLE - Systemic Lupus ErythematosusSSc-Systemic SclerosisIIM- Idiopathic Inflammatory Myopathies
CytoCares Inc6 enrolled1 locationNCT07193810
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Idiopathic Inflammatory MyopathiesSystemic Sclerosis
Nkarta, Inc.144 enrolled15 locationsNCT06733935
Recruiting
Phase 2

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals123 enrolled55 locationsNCT06665256
Recruiting
Phase 1

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

Systemic Lupus Erythematosus (SLE)Idiopathic Inflammatory Myopathies(IIM)
Nanjing Legend Biotech Co.38 enrolled5 locationsNCT07331272
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

ANCA Associated Vasculitis (AAV)SLE - Systemic Lupus ErythematosusSSc-Systemic Sclerosis+3 more
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07315087
Recruiting
Early Phase 1

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Idiopathic Inflammatory MyopathiesSporadic Inclusion Body Myositis (sIBM)
Austin Neuromuscular Center10 enrolled2 locationsNCT06479863
Recruiting
Phase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Systemic Sclerosis (SSc)Refractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)
Artiva Biotherapeutics, Inc.90 enrolled26 locationsNCT06991114
Recruiting
Early Phase 1

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

Idiopathic Inflammatory Myopathies(IIM)
Shanghai Cell Therapy Group Co.,Ltd20 enrolled1 locationNCT07174843
Recruiting
Phase 1Phase 2

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Myasthenia GravisNMO Spectrum DisorderChronic Inflammatory Demyelinating Polyradiculoneuropathy+1 more
Tianjin Medical University General Hospital27 enrolled1 locationNCT07022197
Recruiting

AYLo - AutoimmunitY and Loss of y

Asthma BronchialeCOPDSarcoidosis+10 more
University of Bonn500 enrolled1 locationNCT06696027
Recruiting

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS

Idiopathic Inflammatory MyopathiesGiant Cell ArteritisPolymyalgia Rheumatica+1 more
University Hospital, Brest300 enrolled11 locationsNCT04664465
Recruiting
Not Applicable

Adult Autoimmune Myopathies (MAIA)

Idiopathic Inflammatory Myopathies
University Hospital, Brest60 enrolled1 locationNCT04792931
Recruiting

Optimizing Treatment on Idiopathic Inflammatory Myopathies

Idiopathic Inflammatory Myopathies
University of Sao Paulo60 enrolled1 locationNCT03092180
Recruiting

Biomarkers in Autoimmune Disease of Nervous System

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+8 more
Tongji Hospital50,000 enrolled1 locationNCT06502015
Recruiting
Early Phase 1

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+7 more
Tongji Hospital36 enrolled1 locationNCT04561557